Skip to main content

Advertisement

SpringerLink
Log in

Vaccination in the Elderly and IBD

  • Gastroenterology for Geriatric Patients (S Katz and A Afzali, Section Editors)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose of review

Significant gaps in knowledge and utilization of vaccinations exist among practitioners providing care for patients with IBD. This review is intended to update the reader on best practices for vaccination within the IBD population with a specific focus on the elderly.

Recent findings

Advances in IBD therapeutics have recently increased the number of immunosuppressive therapies available to practitioners. Differences in mechanisms of action of these medications have led to differential implications pertaining to vaccination strategies. Additionally, new vaccines, including the recombinant zoster vaccine, have recently become available for the use in the IBD population.

Summary

Given the prominent role the IBD provider plays in the management of patients with IBD, a clear understanding of best practices is essential. This review provides a framework for the integration of optimal vaccination strategies for practitioners caring for adult and elderly patients with IBD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently are highlighted as follows: • Of importance •• Of major importance

  1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78.

    Google Scholar 

  2. Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39(5):459–77.

    CAS  PubMed  Google Scholar 

  3. Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27(8):617–24.

    PubMed  Google Scholar 

  4. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46(3):336–43.

    Article  PubMed  PubMed Central  Google Scholar 

  5. • Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008;14(2):253–8 This study identified gaps in the receipt of routine preventive care, including vaccinations, within the IBD population.

    PubMed  Google Scholar 

  6. Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci. 2011;56(3):819–24.

    PubMed  Google Scholar 

  7. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17(12):2536–40.

    PubMed  Google Scholar 

  8. Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 2012;18(1):34–40.

    PubMed  Google Scholar 

  9. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578–85.

    CAS  PubMed  Google Scholar 

  10. • Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83–94 This article describes differnences in the immune response to vaccination among elderly patients.

    PubMed  Google Scholar 

  11. Gecse KB, Lakatos PL. IBD in 2016: biologicals and biosimilars in IBD - the road to personalized treatment. Nat Rev Gastroenterol Hepatol. 2017;14(2):74–6.

    PubMed  Google Scholar 

  12. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57(4):549–58.

    CAS  PubMed  Google Scholar 

  13. • Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337–346.e10 Synopsis of infectious risk among patients with IBD. This frames the need for preventive vaccination in this population.

  14. Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10–27.

    PubMed  Google Scholar 

  15. Adult Immunization Schedule by Vaccine and Age Group | CDC [Internet]. [cited 2019 19];Available from: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

  16. Chow EJ, Davis CT, Abd Elal AI, et al. Update: influenza activity - United States and worldwide, May 20-October 13, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(42):1178–85.

    PubMed  PubMed Central  Google Scholar 

  17. Meites E; Kempe A, Markowitz LE. Use of a 2-dose schedule for human papilloma virus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR 2016; 65(49);1405–1408

    PubMed  Google Scholar 

  18. http://www.immunize.org/askexperts/experts_hpv.asp. Accessed June 30, 2019.

  19. •• Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241–58 This important guideline details best practices for preventive care within the IBD patient population with an in-depth description of vaccine recommendations.

    PubMed  Google Scholar 

  20. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100.

    PubMed  Google Scholar 

  21. Rahier J-F, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60(4):456–62.

    PubMed  Google Scholar 

  22. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18(2):261–8.

    PubMed  Google Scholar 

  23. Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine. 2012;30(8):1413–24.

    CAS  PubMed  Google Scholar 

  24. Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: results from a web-based study. Dig Liver Dis. 2018;50(6):563–7.

    PubMed  Google Scholar 

  25. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834–40.

    PubMed  Google Scholar 

  26. Malhi G, Rumman A, Thanabalan R, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439–44.

    PubMed  Google Scholar 

  27. Parker S, Chambers White L, Spangler C, et al. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis. 2013;19(9):1809–14.

    PubMed  Google Scholar 

  28. Reich JS, Miller HL, Wasan SK, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11(6):396–401.

    Google Scholar 

  29. Kasper AK, Pallotta AM, Kovacs CS, Spinner ML. Infectious diseases consult improves vaccination adherence in kidney transplant candidates. Vaccine. 2018;36(34):5112–5.

    CAS  PubMed  Google Scholar 

  30. Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol. 2013;10(5):277–85.

    CAS  PubMed  Google Scholar 

  31. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(4):420–9.

    CAS  PubMed  Google Scholar 

  32. Kim DK, Riley LE, Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(5):158–60.

    PubMed  PubMed Central  Google Scholar 

  33. Narula N, Yamamura DLR, Marshall JK. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can J Gastroenterol. 2010;24(2):121–5.

    PubMed  PubMed Central  Google Scholar 

  34. Chang JY, Jung S-A, Moon CM, Kim S-E, Jung H-K, Shim K-N. Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea. Intest Res. 2018;16(4):599–608.

    PubMed  PubMed Central  Google Scholar 

  35. • Pratt PK, David N, Weber HC, et al. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis. 2018;24(2):380–6 This recent study highlights the potential adverse impact of TNF antagonist therapy on the immunogenicity of the hepatitis B vaccine in the IBD population.

    PubMed  Google Scholar 

  36. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1460–6.

    CAS  PubMed  Google Scholar 

  37. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33 quiz CE1.

  38. Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015;30(11):1591–5.

    CAS  PubMed  Google Scholar 

  39. Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016;61(10):2972–6.

    CAS  PubMed  Google Scholar 

  40. Caldera F, Misch EA, Saha S, et al. Immunosuppression does not affect antibody concentrations to measles, mumps, and rubella in patients with inflammatory bowel disease. Dig Dis Sci. 2019;64(1):189–95.

    CAS  PubMed  Google Scholar 

  41. Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7(4):301–7.

    CAS  PubMed  Google Scholar 

  42. Gelinck LBS, van der Bijl AE, Beyer WEP, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67(5):713–6.

    CAS  PubMed  Google Scholar 

  43. Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8(3):223–33.

    PubMed  Google Scholar 

  44. Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y). 2014;10(6):355–63.

    Google Scholar 

  45. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(7):851–6.

    PubMed  Google Scholar 

  46. deBruyn JCC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(1):25–33.

    PubMed  Google Scholar 

  47. Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012;61(3):385–91.

    PubMed  Google Scholar 

  48. Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci. 2015;60(8):2446–53.

    CAS  PubMed  Google Scholar 

  49. deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–47.

    PubMed  Google Scholar 

  50. • Melmed GY. Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol. 2012;107(1):141–2 This study demonstrates that despite numerous studies demonstrating a blunted immune response to vaccinations among patients with IBD receiving thiopurine immunosuppression, the diminished immune response is still likely sufficient to provide protection against illness, including with influenza.

    PubMed  Google Scholar 

  51. Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16(1):99–105.

    PubMed  Google Scholar 

  52. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–9.

    CAS  PubMed  Google Scholar 

  53. Brogan MD, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987;24(2):69–74.

    CAS  PubMed  Google Scholar 

  54. Nielsen HJ, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36(3):265–9.

    CAS  PubMed  Google Scholar 

  55. Rüddel J, Schleenvoigt BT, Schüler E, Schmidt C, Pletz MW, Stallmach A. Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: a case report. Z Gastroenterol. 2016;54(9):1081–4.

    PubMed  Google Scholar 

  56. Ekenberg C, Friis-Møller N, Ulstrup T, Aalykke C. Inadvertent yellow fever vaccination of a patient with Crohn’s disease treated with infliximab and methotrexate. BMJ Case Rep. 2016;2016.

  57. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–36.

    PubMed  Google Scholar 

  58. Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(7):1293–1301.e5 quiz e70, e72.

    PubMed Central  Google Scholar 

  59. • Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of infection and types of infection among elderly patients with inflammatory bowel disease: a retrospective database analysis. Inflamm Bowel Dis 2019. This large retrospective Truven database study identified an increased risk of pneumonia and sepsis among elderly patients with IBD as compared to those aged 18-64.

  60. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–12.

    PubMed  Google Scholar 

  61. • Kantsø B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977-2013. Am J Gastroenterol. 2015;110(11):1582–7 This study highlights the increased risk of invasive pneumococcal infection within patients with IBD and therefore the importance of proactive immunization in the immunosuppressed population.

    PubMed  Google Scholar 

  62. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(1):148–54.

    PubMed  Google Scholar 

  63. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18(6):1042–7.

    PubMed  Google Scholar 

  64. van Aalst M, Garrido HMG, van der Leun J, et al. Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease. Clin Infect Dis 2019;

  65. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481–6.

    CAS  PubMed  Google Scholar 

  67. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.

    PubMed  Google Scholar 

  68. Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927.e3.

    PubMed  Google Scholar 

  69. Nugent Z, Singh H, Targownik LE, Bernstein CN. Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: is there still an unmet need? Inflamm Bowel Dis. 2019;25(3):532–40.

    PubMed  Google Scholar 

  70. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.

    CAS  PubMed  Google Scholar 

  73. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.

    CAS  PubMed  Google Scholar 

  74. Meserve J, Aniwan S, Koliani-Pace JL, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018; 17(8):1533-1540.e2

    PubMed  Google Scholar 

  75. Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Lukin DJ, Weiss A, Aniwan S, et al. 277 - Comparative safety profile of vedolizumab and tumor necrosis factor-antagonist therapy for inflammatory bowel disease: a multicenter consortium propensity score-matched analysis. Gastroenterology. 2018;154(6):S-68.

    Google Scholar 

  77. Schreiber S, Peyrin-Biroulet L, Loftus EV, et al. OP34 VARSITY: a double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. J Crohn's Colitis. 2019;13(Supplement_1):S612–3.

    Google Scholar 

  78. Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Navaneethan U, Edminister T, Zhu X, Kommaraju K, Glover S. Vedolizumab is safe and effective in elderly patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):E17.

    PubMed  Google Scholar 

  80. Harrington JE, Hamilton RE, Wasan SK, Farraye FA, Ganley-Leal L. Immunogenicity of the influenza vaccine in IBD patients treated with vedolizumab. American Journal of Gastroenterology 2018;113(Supplement):S407–8.

    Google Scholar 

  81. • Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83. Vedolizumab as a gut-selective lymphocyte trafficking inhibitor which does not cause systemic immunosuppression. This study shows that immunogenicity to oral antigens but not parenterally administered antigens is impaired by vedolizumab. The “gut-selectivity” leads to preserved systemic immune function, leading to the recommendation that live parenteral vaccines will not place patients at risk for infection.

    PubMed  Google Scholar 

  82. UC A. ENTYVIO (vedolizumab) for injection, for intravenous use [Internet]. [cited 2019 28];Available from: https://www.accessdata.fda.gov/drugsaftda_docs/label/2014/125476s000lbl.pdf. Accessed June 30, 2019.

  83. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) Suspension for Intramuscular Injection [Internet]. [cited 2019 26];Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix. Accessed June 30, 2019.

  84. • Reich J, Pei-Hsuan L, Zahorian T, Noronha A, Wasan SK, Farraye FA. P2231 - use of recombinant zoster vaccine (RZV-Shingrix) in patients with inflammatory bowel disease. ACG 2018 Annual Scientific Meeting Abastracts 2018 ;This is the first report of the use of the recombinant zoster vaccine among patients with IBD. While the size was limited, immunogenicity appears comparable with the general population.

  85. Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–65.

    PubMed  PubMed Central  Google Scholar 

  86. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.

    CAS  PubMed  Google Scholar 

  87. Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2018;17(8):1541–50.

    PubMed  Google Scholar 

  88. IBD Checklist for Monitoring & Prevention [Internet]. [cited 2019 Apr 19];Available from: http://www.cornerstoneshealth.org/wp-content/uploads/2018/08/Monitoring-and-Prevention-8.31.18.pdf. Accessed June 30, 2019.

  89. IBD and Keeping up with Immunization [Internet]. [cited 2019 18];Available from: https://www.crohnscolitisfoundation.org/assets/pdfs/factsheetimmunization.pdf. Accessed June 30, 2019.

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, USA

    Anthony J. Choi MD, Preston Atteberry MD & Dana J. Lukin MD, PhD

  2. Jill Roberts Center for IBD, New York Presbyterian Hospital-Weill Cornell Medical College, 1315 York Avenue Mezzinine SM1A15, New York, NY, 10021, USA

    Dana J. Lukin MD, PhD

Authors
  1. Anthony J. Choi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Preston Atteberry MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dana J. Lukin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Authored first draft (AC, DJL), critical revisions (all), approved final draft (all).

Corresponding author

Correspondence to Dana J. Lukin MD, PhD.

Ethics declarations

Conflict of Interest

Dana Lukin reports grants and personal fees from Abbvie; personal fees from Janssen, Pfizer, Prometheus, Celgene, and Salix; and educational grants from Takeda. Anthony Choi declares that he has no conflict of interest. Preston Atteberry declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Gastroenterology for Geriatric Patients

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choi, A.J., Atteberry, P. & Lukin, D.J. Vaccination in the Elderly and IBD. Curr Treat Options Gastro 17, 492–505 (2019). https://doi.org/10.1007/s11938-019-00257-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-019-00257-y

Keywords

Search

Navigation